TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04910412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
Study: NCT06691776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: online CBCT-guided adaptive radiation therapy using a new software
Description: Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: online CBCT-guided adaptive radiation therapy using a new software
Description: Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: online CBCT-guided adaptive radiation therapy using a new software
Description: Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.
Study: NCT06302322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thin Tissues
Description: Patients with thin tissues received implants 10 years ago and are now followed up after 10 years.
Study: NCT06691776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: online CBCT-guided adaptive radiation therapy using a new software
Description: Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: online CBCT-guided adaptive radiation therapy using a new software
Description: Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.
Study: NCT06691048

Intervention type: OTHER
Intervention: Description of an adult population diagnosed late with a neurodevelopmental disorder
Description: Clinical description during diagnostic interview
Study: NCT06694714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 ml lidocaine + epinephrine 1:100,000
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 ml lidocaine + epinephrine 1:100,000
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
Study: NCT06302322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thick Tissues
Description: Patients with thick tissues received implants 10 years ago and are now followed up after 10 years.
Study: NCT06694714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 ml lidocaine + epinephrine 1:100,000
Description: 1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 ml lidocaine + epinephrine 1:100,000
Description: 1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
Study: NCT06689228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rational Drug Use Training
Description: Rational Drug Use Training and Tele-monitoring will include information on drugs and their importance, rational drug use, rational drug use in haemodialysis patients, harms of irrational drug use, benefits of rational drug use, obstacles encountered in rational drug use, ways to overcome obstacles encountered in rational drug use, and increasing self-efficacy. The first training is planned to last approximately 30-35 minutes for each patient and the second training (summary training) is planned to last approximately 15-20 minutes. With telemonitoring, reminder messages will be sent to patients' phones at intervals.
Study: NCT05722171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gdT cell injection targeting B7-H3 chimeric antigen receptor
Description: The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.
Study: NCT05284721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Peer Navigator for Early Psychosis
Description: The Family Peer Navigator model is theoretical underpinning by the Social-Ecological Model and the Social Cognitive Theory, that incorporates a mixture of evidence- and research-based strategies, to include three key components: 1) Introduction and Assessment; 2) Individual Psychoeducation; 3) Six Brief Check-In

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordination
Description: active control, treatment as usual including services provided by the coordinated specialty care program for first-episode psychosis.
Study: NCT06302322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgically augmented thin tissues
Description: Patients with thin tissues received soft tissue augmentation and implants 10 years ago and are now followed up after 10 years.
Study: NCT05153395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon dioxide breathing
Description: Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon dioxide breathing
Description: Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
Study: NCT05679921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, pazopanib
Description: Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, pazopanib
Description: Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
Study: NCT05153395

Intervention type: OTHER
Group type: OTHER
Intervention: Carbon dioxide breathing
Description: Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurovascular Coupling
Description: Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
Study: NCT04961216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMISE
Description: Self-regulation intervention
Study: NCT06363435

Intervention type: DEVICE
Intervention: AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans
Description: Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients
Study: NCT05862870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: painTRAINER
Description: patient self-administered pain management web application
Study: NCT05255263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PIEB
Description: Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CEI
Description: Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
Study: NCT04349111

Intervention type: RADIATION
Group type: OTHER
Intervention: Intra-operative Radiation Therapy - IORT
Description: Single dose of 20 Gy
Study: NCT05625217

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Total Body PET/CT Imagin
Description: Total-body PET imaging at different timepoints
Study: NCT05655481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance training with rehabilitation
Description: Effects of home telerehabilitation program improve functional capacity variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Telehealth and guidelines for the practice of physical activity and health education
Study: NCT06478875

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: [68Ga]Ga-PentixaFor PET imaging
Description: PET imaging of adrenal glands
Study: NCT06140160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: To carry out an additional measurement using Doppler ultrasound (non-invasive examination). Doppler ultrasound measurements of the diameter and length of the perforating artery using a high-frequency Doppler ultrasound probe following a Doppler ultrasound of the supra-aortic trunks.
Study: NCT06359795

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT
Description: Patients underwent 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within 10 days.
Study: NCT05153395

Intervention type: OTHER
Group type: OTHER
Intervention: Neurovascular Coupling
Description: Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
Study: NCT04463615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study: NCT05139979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing and Wellness Webinar
Description: Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Daily Activity
Description: Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
Study: NCT05496803

Intervention type: OTHER
Group type: OTHER
Intervention: routine education plus digital video disk
Description: Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.

Intervention type: OTHER
Group type: OTHER
Intervention: routine education
Description: Parents receiving routine education before their children receiving congenital heart disease catheterization
Study: NCT06219148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy Telehealth
Description: Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Music Therapy Telehealth
Description: Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-Collaborative Social Work Telehealth
Description: Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Social Work Telehealth
Description: Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
Study: NCT06686355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqilishui formula
Description: Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 5% Yiqilishui Granules + 95% Dextrin;
Study: NCT06694844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation with M1
Description: Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M1 membrane (peramem membrane).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation with M2
Description: Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M2 membrane (Cytoplast membrane).
Study: NCT04849507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
Study: NCT05362799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozol (Femara, Novartis)
Description: Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)
Description: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)
Description: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
Description: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
Study: NCT05704049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
Study: NCT06089707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Nasal Spray
Description: IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Nasal Spray
Description: IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
Study: NCT05318066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate and Norepinephrine infusion
Description: Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate and Norepinephrine infusion
Description: Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.
Study: NCT05605574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning conversations
Description: In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
Study: NCT05704049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV